Detail akcie CHUGAI PHARM online

Business Summary: CHUGAI PHARMACEUTICAL CO., LTD. is a Japan-based company mainly engaged in the research, development, manufacture, sale, import and export of pharmaceutical products. The pharmaceutical products and medical devices for patients include ACTEMRA, Avastin, ALECENSA, Kadcyla, GAZYVA, CellCept, Zelboraf, Xeloda, Tamiflu, Tarceva, Tecentriq, Herceptin, Perjeta, cancer gene panel testing and others. These products are primarily used to treat conditions such as cancer, kidney disease and kidney transplantation, bone and joint diseases (rheumatoid arthritis), neurological and muscular diseases (neuromyelitis optica spectrum disorders, spinal muscular atrophy, and Duchenne muscular dystrophy), blood disorders (hemophilia and paroxysmal nocturnal hemoglobinuria), and eye diseases (retinal disorders). It also engages in administrative operations, the provision of scientific information on pharmaceuticals, investment activities, and the provision of influenza information services.
Financial Summary: BRIEF: For the six months ended 30 June 2026, Chugai Pharmaceutical Co Ltd revenues increased 15% to Y663.33B. Net income applicable to common stockholders increased 19% to Y231.75B. Revenues reflect Switzerland segment increase of 15% to Y389.2B, Other foreign segment increase from Y16.58B to Y35.85B, Japan segment increase of 6% to Y238.29B. Net income benefited from Pharmaceuticals business segment income increase of 17% to Y319.62B.